This technology is a P2X4 or P2X7 purine receptor-targeted therapy for the treatment of shock-induced multiple organ failure.
There is a critical unmet need for therapies that go beyond symptom management in shock-induced multiple organ failure. Current treatments do not target the underlying pathophysiological mechanisms driving organ dysfunction. Emerging evidence suggests that pharmacological agents capable of binding to specific biological receptors may offer a way to prevent or mitigate cellular damage by stabilizing intracellular and extracellular processes during and after shock.
This technology identifies the purine receptors P2X4 and P2X7 as treatment targets for treating shock-induced organ injury and inflammation. Trauma and hemorrhagic shock increase ATP levels, activating P2X4 and P2X7, which initiates inflammation and organ injury. Blocking these purine receptors with antagonists, antagonistic nanobodies, or other methods may present a promising approach to protect against trauma and shock-induced multiple organ failure.
This technology has been validated in in vivo models of human trauma-related shock.
IR CU25052
Licensing Contact: Kristin Neuman
